Navigation Links
ivWatch Awarded New Innovative Technology Contract From Vizient, Inc
Date:8/29/2017

HAMPTON, Va., Aug. 29, 2017 /PRNewswire/ -- ivWatch, LLC, the leading provider of continuous monitoring devices for the early detection of peripheral IV infiltrations, announced it has been awarded an Innovative Technology contract from Vizient, Inc., the largest member-driven health care performance improvement company in the country.

A continuous monitoring device to aid in the early detection of peripheral IV infiltration and extravasation events
A continuous monitoring device to aid in the early detection of peripheral IV infiltration and extravasation events

The Innovative Technology contract was awarded to ivWatch based on recommendations for the ivWatch Model 400 device by providers with expertise in this category who serve on one of Vizient's member-led councils. Innovative Technology contracts are reserved for technologies that demonstrate an ability to enhance clinical care or patient safety, and those that improve an organization's care delivery and business model.

The ivWatch Model 400 continuously monitors a patient's peripheral IV for evidence of infiltrations, which occur when medication or fluid leaks into the surrounding tissue. Intravenous therapy is a routine part of treatment for nearly 80 percent of patients in the U.S., yet more than 20 percent of these IVs may fail because of infiltration, risking both a serious drug delivery error and tissue damage. Earlier detection of those failures, via ivWatch sensor technology, is the new and next step in minimizing this potential for injury.

"The Innovative Technology contract gives Vizient's diverse membership a simple and more affordable means for adopting continuous IV monitoring and validates the excitement we've seen in hospitals across the country about our unique technology," said Gary Warren, president and CEO of ivWatch, LLC. "IV infiltration is a major problem that can lead to serious medical complications and even amputation. This contract with Vizient is one more step towards our vision of eliminating the harm associated with IV infiltrations."

"Due to the number of products and services being released and marketed as 'innovative,' member hospitals truly value the thorough innovative technology review process in place at Vizient to help them identify products worth further evaluation at their own facilities," said Debbie Archer, director of procurement and leader of Vizient's Innovative Technology program for suppliers. "After a full review of the ivWatch Model 400, Vizient's member council agreed this solution offers unique and incremental benefits over other products available on the market today, and recommended it for an Innovative Technology contract. We are pleased to award this new contract to ivWatch."

Vizient, Inc. represents the combined strengths of the organizations formerly known as VHA Inc., University HealthSystem Consortium, Novation and MedAssets' Spend and Clinical Resource Management. Since 2003, nearly 2200 new and innovative products and technologies have been submitted through the Vizient Innovative Technology program. Vizient works with member-led councils and task forces to identify and review potentially innovative products. If it is determined that a product is innovative, a contract may be awarded outside of Vizient's competitive bid cycle.

About ivWatch, LLC

ivWatch is a medical device and biosensor company focused on improving the safety and effectiveness of intravenous (IV) therapy through early detection of infiltrations. The Model 400 provides a first-of-its-kind, FDA-cleared, noninvasive medical device that continuously monitors peripheral IVs for infiltration and extravasation events. The ivWatch Model 400 aims to help eliminate patient harm associated with adverse events and to reduce drug delivery errors. The ivWatch OEM Board integrates ivWatch technology into existing products, enabling OEMs to help healthcare providers deliver a higher level of patient care and to reduce risks related to IV therapy. Follow us on Twitter@ivWatch or Facebook @ivWatchLLC. www.ivWatch.com

MEDIA CONTACT: Leah Moore, leah.moore@ivwatch.com, Office (855) 489-2824 x7031, Mobile (757) 839-5653

The ivWatch OEM Board is not an FDA-cleared device. It is the responsibility of the Original Equipment Manufacturer integrating ivWatch technology to secure the proper regulatory clearance.

View original content with multimedia:http://www.prnewswire.com/news-releases/ivwatch-awarded-new-innovative-technology-contract-from-vizient-inc-300510676.html


'/>"/>
SOURCE ivWatch, LLC
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. ivWatch Receives FDA Clearance and Significantly Advances Safety of IV Therapy
2. ivWatch, LLC Receives 2016 Virginia Governors Outstanding STEM Award for Science Innovation
3. ivWatch Launches OEM Solution, Expands Executive Team to Support Global Sales and Partnerships
4. ivWatch Wins Top Honors at 2017 Medical Design Excellence Awards
5. AnaptysBio Awarded U.S. Government Contract To Develop Anti-Ricin Antibodies
6. Cempra Awarded $58 Million Contract to Develop Antibiotic for Pediatric Use and Biodefense by Biomedical Advanced Research and Development Authority (BARDA)
7. Oramed Pharmaceuticals Awarded Grant by the Office of the Chief Scientist of Israel
8. NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of ND0612 for Parkinsons Disease
9. Tunitas Therapeutics Awarded Phase II SBIR Grant to Advance Asthma Program
10. Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies
11. Great Lakes NeuroTechnologies Awarded Patent For Technology To Treat Parkinsons Disease With Brain Stimulation During Sleep
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... , Sept. 6, 2017   PDI , a leader ... will host an educational session focused on the role ... (CLABSI) prevention at the 2017 Annual Scientific Meeting of ... take place at the Phoenix ... from Sept. 16-19, will also feature PDI,s Prevantics® ...
(Date:9/5/2017)... 2017 Sapheneia and Scannerside received FDA 510(k) ... is a third-party Vendor neutral CT product that makes ... compliance with current MITA standards. ... solution is specifically designed to provide CT operators, prior ... doses over a predefined threshold. Scannerside Dose Check is ...
(Date:9/5/2017)... 5, 2017  Just 18 months after its February ... to announce the appointment of three new senior people ... Dominic Jones-Phillips and James Wright ... Tammy Wynne joins ... access writers. She has over ten years, experience in ...
Breaking Medicine Technology:
(Date:9/22/2017)... (PRWEB) , ... September 22, 2017 , ... ... operations and financial setbacks, a senior finds a new lease on life with ... helped thousands of people resolve their problem with unsecured debt. The senior is ...
(Date:9/22/2017)... ... September 22, 2017 , ... “Cursed with ... an obligatory tithe, and the freedom experienced when breaking free from this misconception. ... author, Lysa M. Harrison. , Published by Christian Faith Publishing, Lysa M. Harrison’s ...
(Date:9/22/2017)... ... ... “Fruit of the Spirit: “Love””: a delightful adventure of two friends who play ... Spirit: “Love”” is the creation of published author, Halimah Jones, who was born and ... an avid writer, her inspiration for “Fruit of the Spirit: “Love”” blossomed from her ...
(Date:9/21/2017)... ... September 21, 2017 , ... With ProSlideshow Portrait from Pixel Film Studios ... Users can select from up to two layers of subject matter along with fully ... all within Final Cut Pro X. , With ProSlideshow Portrait each user ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... ... **An FDAnews Management Report**, http://www.fdanews.com/products/54818-promotional-communication      , In the competitive world of ... can get while staying in compliance with FDA rules. , The FDA has ...
Breaking Medicine News(10 mins):